Filtered By:
Drug: Ranibizumab Injection

This page shows you your search results in order of date.

Order by Relevance | Date

Total 67 results found since Jan 2013.

Associations between vision impairment and vision-related interventions on crash risk and driving cessation: systematic review and meta-analysis
Conclusion Impaired vision identified through a variety of measures is associated with both increased MVC involvement and cessation. Cataract surgery can reduce MVC risk. Despite literature being highly heterogeneous, this review shows that detection of vision problems and appropriate treatment are critical to road safety. PROSPERO registration number CRD42020172153.
Source: BMJ Open - August 11, 2023 Category: General Medicine Authors: Nguyen, H., Di Tanna, G. L., Coxon, K., Brown, J., Ren, K., Ramke, J., Burton, M. J., Gordon, I., Zhang, J. H., Furtado, J., Mdala, S., Kitema, G. F., Keay, L. Tags: Open access, Ophthalmology Source Type: research

Anti-vascular endothelial growth factor for neovascular glaucoma
CONCLUSIONS: Anti-VEGFs as an adjunct to conventional treatment could help reduce IOP in NVG in the short term (four to six weeks), but there is no evidence that this is likely in the longer term. Currently available evidence regarding the short- and long-term effectiveness and safety of anti-VEGFs in achieving control of IOP, visual acuity, and complete regression of new iris vessels in NVG is insufficient. More research is needed to investigate the effect of these medications compared with, or in addition to, conventional surgical or medical treatment in achieving these outcomes in NVG.PMID:37010901 | PMC:PMC10069372 | D...
Source: Cochrane Database of Systematic Reviews - April 3, 2023 Category: General Medicine Authors: Thanitsara Rittiphairoj Gloria Roberti Manuele Michelessi Source Type: research

Two-year clinical outcomes of triple therapy with photodynamic therapy, anti-vascular endothelial growth factor agent, and triamcinolone acetonide for neovascular age-related macular degeneration
ConclusionIn nAMD patients, induction treatment with triple therapy resulted in approximately 40% of the patients requiring no retreatment for 2 years. The type of anti-VEGF agents used made no difference in the results.
Source: Japanese Journal of Ophthalmology - November 8, 2022 Category: Opthalmology Source Type: research

Prognostic Evaluation of Vitrectomy Assisted by Lucentis in Diabetic Retinopathy and Neovascular Glaucoma
Evid Based Complement Alternat Med. 2022 Aug 1;2022:4127293. doi: 10.1155/2022/4127293. eCollection 2022.ABSTRACTFor verifying the prognosis of Lucentis-assisted vitrectomy (PPV) in diabetic retinopathy (DR) and neovascular glaucoma (NVG), a retrospective analysis of DR and NVG patients who were admitted to our hospital from July 2019 to December 2020 was conducted. According to the treatment protocol, subjects who had PPV intervention were in the control group (CG; n = 38) and those receiving Lucentis adjunctive PPV were included in the intervention group (RG; n = 40). The indicators between groups were listed: treatment ...
Source: Evidence-based Complementary and Alternative Medicine - August 12, 2022 Category: Complementary Medicine Authors: Xuli Zhao Yakun Wang Source Type: research

Comparison of risks of arterial thromboembolic events and glaucoma with ranibizumab and aflibercept intravitreous injection: A nationwide population ‐based cohort study
ConclusionsNo significant differences in the risk of major ATEs and glaucoma were found between ranibizumab and aflibercept, and aflibercept might be safe for use in elderly patients.
Source: PLoS One - April 18, 2022 Category: Biomedical Science Authors: Yin-Hsi Chang Source Type: research

Clinical observation of ranibizumab combined with surgery in the treatment of neovascular glaucoma with vitreous hemorrhage
ConclusionIntravitreal injection of ranibizumab can effectively promote the rapid regression of intraocular neovascularization and help to control the IOP and improve postoperative visual acuity.
Source: International Ophthalmology - April 1, 2022 Category: Opthalmology Source Type: research

The Efficacy of Simultaneous Injection of Dexamethasone Implant and Ranibizumab Into Vitreous Cavity on Macular Edema Secondary to Central Retinal Vein Occlusion
The purpose of this study was to determine the safety and effectiveness of simultaneous vitreous injection of dexamethasone implant and ranibizumab on macular edema secondary to central retinal vein occlusion (CRVO). We conducted a 6-month retrospective self-control study. Twenty-five patients diagnosed with macular edema secondary to CRVO were enrolled in this study. The patients received intravitreal injection of dexamethasone implant and ranibizumab. The changes in best corrected visual acuity (BCVA), central retinal thickness (CRT) and interocular pressure (IOP) before and at 2w, 1, 2, 3, 4, 5, 6 m after injection wer...
Source: Frontiers in Pharmacology - March 1, 2022 Category: Drugs & Pharmacology Source Type: research

Postprocedural Endophthalmitis or Postprocedural Intraocular Inflammation: A Diagnostic Conundrum
We experienced an atypical endophthalmitis occurring post consecutively performed in-office procedures; an intravitreal injection (IVI) of ranibizumab followed by an anterior chamber (AC) paracentesis performed twice in an eye with neovascular glaucoma (NVG). A 52-year-old diabetic male who was asymptomatic developed signs of endophthalmitis and decreased vision without pain in his left eye a few days post-IVI and AC paracentesis. The condition worsened after an initial vitreous tap and injection of antibiotics. Cultures of vitreous and aqueous samples were negative. Complete resolution occurred after a pars plana vitrecto...
Source: Case Reports in Ophthalmology - May 11, 2021 Category: Opthalmology Source Type: research

Comparison of conbercept and ranibizumab combined mitomycin C-augmented trabeculectomy for neovascular glaucoma
ConclusionThe conbercept effects were similar with that of ranibizumab. Intravitreal injection of conbercept was effective for NVG treatment, which provides a new therapeutic drug for NVG treatment.
Source: International Ophthalmology - April 24, 2021 Category: Opthalmology Source Type: research

Intravitreal anti-vascular endothelial growth factor medications during pregnancy: current perspective
ConclusionWomen of childbearing age should be consulted regarding the potential adverse effects of anti-VEGF medications on fetal health and the risk of early pregnancy loss. They should be strongly encouraged to use appropriate contraceptive methods during treatment. A timely obstetrics consultation may help in this situation. Attempt for pregnancy should be withheld for at least 3  months following last injection of ranibizumab and aflibercept, and for at least 6 months following last injection of bevacizumab.
Source: International Ophthalmology - February 1, 2021 Category: Opthalmology Source Type: research

Sustained Elevation of Intraocular Pressure After Administration of Intravitreal Anti-Vascular Endothelial Growth Factor Agents in Patients With and Without Pseudoexfoliation Syndrome
Précis: Intravitreal anti-vascular endothelial growth factor therapy resulted in sustained elevation of intraocular pressure (IOP) in 18.6% of patients with coexisting age-related macular degeneration and pseudoexfoliation (PXF) syndrome. The development of sustained elevation of IOP after ~19 injections reflected the cumulative effect of anti-vascular endothelial growth factor injections on IOP. Purpose: The purpose of this study was to compare the long-term effect of intravitreal ranibizumab (IVR) and intravitreal bevacizumab (IVB) therapies on IOP in patients with and without PXF syndrome. Design: This was a re...
Source: Journal of Glaucoma - October 1, 2020 Category: Opthalmology Tags: Original Studies Source Type: research

Ghost cell glaucoma after intravitreous injection of ranibizumab in proliferative diabetic retinopathy
The development of ghost cell glaucoma in patients with proliferative diabetic retinopathy (PDR) after intravitreous injection (IV) was rare. Here we reported a series of patients with PDR who received Intravi...
Source: BMC Ophthalmology - April 15, 2020 Category: Opthalmology Authors: Jun Xu, Meng Zhao, Ji peng Li and Ning pu Liu Tags: Research article Source Type: research

Sustained Intraocular Pressure Rise after the Treat and Extend Regimen at 3 Years: Aflibercept versus Ranibizumab.
Conclusion: IOP rise is an important consideration as the chronicity of the condition can eventually lead to glaucomatous changes in eyes with already compromised vision. Follow-ups and use of appropriate therapy can be determined correspondingly. PMID: 32051764 [PubMed]
Source: Journal of Ophthalmology - February 15, 2020 Category: Opthalmology Tags: J Ophthalmol Source Type: research